Neurodegeneration

CENTRAL NERVOUS SYSTEM

Porsolt offers models in all areas of psychopharmacology, epilepsy, sleep-wake, and neurodegenerative disorders. We are uniquely placed to offer a full range of CNS efficacy and safety pharmacology assessments, from basic models and regulatory tests, through the evaluation of abuse and dependence liability and proconvulsant risk using EEG.

Neurodegeneration

Alzheimer’s and diseases (AD and PD) usually appear later in life, typically in people older than 50 years of age.

AD is characterized by memory deficits and rarely by movement impairment, whereas PD is primarily a movement disorder accompanied, in some cases, by memory impairments.

AD | PD

EARLY PHASE

LATE PHASE

Alzheimer’s disease

Mild cognitive impairment

No clear motor impairments

Dementia in most of cases

No clear motor impairments

Parkinson’s disease

Mild cognitive impairment

Slight motor impairments

Dementia in most of cases

Marked motor impairments

Parkinson's disease

Unilateral complete lesion of the nigro-striatal pathway
Motor impairments for the paw contralateral to the lesion
L-DOPA, gold standard treatment, partially improves motor deficit

> Suggested approach
- Neuroprotection: Treatments administered a few hours after lesion and/or chronically during 15 days.
- Improvement of motor symptoms: Treatments administered acutely on the testing day.

> Other avalaible tests:
- Screening: Evaluation of the number of contralateral rotations
- Side effects induced by repeated L-DOPA administrations: Evaluation of dyskinesias
- Lesion size induced by 6-OHDA: Evaluation of TH immunoreactivity

IN VITRO MODELS OF PARKINSON'S DISEASE

Alzheimer’s disease

• Streptozotocin (STZ) - induced cognitive deficit.

> Suggested approach:
 - Evaluation of motor coordination:  Morris water maze  / delayed alternation

ALZHEIMER'S DISEASE & TAUOPATHY

Dowload our latest posters: